T10635 |
Burixafor hydrobromide
|
1191450-19-7
|
98%
|
|
Burixafor hydrobromide (TG-0054 hydrobromide) is an orally bioavailable and potent CXCR4 antagonist and an anti-angiogenic drug that is of potential value in tre...
|
T78879 |
CXCR4-IN-2
|
|
98%
|
|
CXCR4-IN-2 (compound A1), a potent bifunctional fluorinated small molecule, inhibits CXCR4 and exhibits anticancer properties by exerting cytotoxicity (IC 50: 60...
|
T79059 |
CXCR4-IN-1
|
2304750-48-7
|
98%
|
|
CXCR4-IN-1 (Example C5), with an IC50 of 20 nM, is a potent inhibitor of CXCR4, applicable for the research of various conditions such as cancer, HIV, diabetic r...
|
T79070 |
Pentixafor
|
1341207-62-2
|
98%
|
|
Pentixafor is a peptide that selectively targets the CXCR4 receptor and can be labeled with Gallium-68 (68Ga) for visualization using positron emission tomograph...
|
T80130 |
SDF-1α (human)
|
1268129-65-2
|
98%
|
|
SDF-1α (human) serves as a chemotactic agent for mononuclear cells through its interaction with the CXCR4 receptor, facilitating critical biological processes su...
|
T80216 |
DOTA-CXCR4-L
|
|
98%
|
|
DOTA-CXCR4-L, a peptide targeting the CXCR4 receptor, is utilized in cancer research, notably in the contexts of glioblastoma and triple-negative breast cancer [...
|
T80525 |
E70K
|
|
98%
|
|
E70K, a CXCL8 C-terminal peptide, features a lysine (K) substitution for glutamic acid (E) at position 70 and has demonstrated the ability to attenuate neutrophi...
|
T11140 |
E6130
|
1427058-33-0
|
98%
|
|
E6130 may be effective in the treatment of inflammatory bowel disease and is a highly selective CX3CR1 regulator for oral administration.
|
T16933 |
SRT3190
|
1204707-73-2
|
98%
|
|
SRT3190 is an antagonist of CXCR2.
|
T12269L |
NUCC-390 dihydrochloride (1060524-97-1 free base)
|
T12269L
|
98%
|
|
NUCC-390 dihydrochloride is selective agonist of small-molecule CXCR4 receptor.
|
TN5227 |
(+/-)-Vestitol
|
56701-24-7
|
98%
|
|
Vestitol has antioxidation, anti-inflammatory and antimicrobial activities, it can strongly act in a low dose and concentration and have a promising potential to...
|
T16864 |
SCH 563705
|
473728-58-4
|
98%
|
|
SCH 563705 is an effective and orally available CXCR2 and CXCR1 antagonist (IC50s: 1.3 nM, 7.3 nM and Kis of 1 and 3 nM, respectively).
|
T19386 |
ITIC
|
1664293-06-4
|
98%
|
|
ITIC, a non-fullerene acceptor, demonstrates exceptional thermal stability and exhibits a glass-crystal transition at a significantly lower temperature than its ...
|
T6764 |
ATI-2341
|
1337878-62-2
|
98%
|
|
ATI-2341, pepducin targeting the C-X-C chemokine receptor type 4 (CXCR4), is an allosteric agonist activating the inhibitory heterotrimeric G protein (Gi) to pro...
|
T19385 |
ITIC-4F
|
2097998-59-7
|
98%
|
|
ITIC-4F, an indacenodithienothiophene (IDTT)-based postfullerene electron acceptor, exhibits wide applicability in high-efficiency binary and ternary single-junc...
|
TP2141 |
Balixafortide TFA (1051366-32-5 free base)
|
TP2141
|
98%
|
|
Balixafortide TFA (POL6326 TFA) is a selective, well-tolerated peptidic CXCR4 antagonist (IC50 < 10 nM). It shows 1000-fold selective for CXCR4 than a large pane...
|
T14665 |
Motixafortide
|
664334-36-5
|
98%
|
|
Motixafortide (BKT140 4-fluorobenzoyl) is an antagonist of CXCR4 (IC50: 1 nM).
|
TP2141L |
Balixafortide
|
1051366-32-5
|
98%
|
|
Balixafortide (POL6326) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC50 < 10 nM and it is also a potent hematopoietic stem and prog...
|
T0801 |
Tannic acid
|
1401-55-4
|
AR
|
|
Tannic acid (Gallotannic acid) is a novel hERG channel blocker.
|
T1739 |
WZ811
|
55778-02-4
|
99.93%
|
|
WZ811 is a novel and effective small molecular CXCR4 antagonist (EC50: 0.3 nM).
|